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Nicotine is a pharmacological active compound found in the tobacco plant, and works as a a 
stimulant of the central nervous system. Evidence is presented that use of nicotine may have 
beneficial effects on athletes’ performance. Nicotine is known to cause weight loss and to 
improve mental capacity by enhancing concentration and relieving anxiety. Additionally, 
improved exercise endurance after nicotine administration has been demonstrated. By using 
nicotine containing medications or smokeless tobacco products, athletes can benefit from 
these effects without most of the health risk associated with smoking.  
 
Nicotine is primarily consumed in the form of tobacco, but a large variety of nicotine 
containing medications exists as well. The most common forms of tobacco consumption 
patterns are smoking as cigarette and pipes, and smokeless tobacco, in the form of chewing 
tobacco, snus and snuff. Depending on the type of product, the tobacco compositions of 
nicotine, and other compounds naturally present in tobacco, differ to a large extent. Levels of 
each compound measurable in biological fluids depend on the chemical composition and the 
distinct pharmacokinetic profile of the consumed product. Theoretically, these variations in 
levels of investigated compounds could be used to differentiate between nicotine consumption 
patterns.  
 
In this project, compounds of interest for discriminating between the use of smoke and 
smokeless tobacco were identified and an LC-MS/MS method involving SPE sample 
preparation was developed and validated in order to determine concentration levels of these 
compounds in urine specimens. Further, concentration levels of these molecules were 
measured in urine specimens from smokers and smokeless tobacco users, and interpretation of 
preliminary results indicated some variability. Still there is a long way to go before the 
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3.1 Doping in sports 
The term doping can be defined as a practice that consists in the absorbtion of specific 
substances or the practice of specific medical acts in order to artificially enhance one’s 
physical or mental capacities[2]. Doping creates different conditions of competition, and 
might as well represent an actual or potential health risk to the athlete[3]. 
Doping is not a new phenomenon, either in sport or society in general. Doping has been 
accepted in many cultures, including the western one. In some sports doping has a long 
tradition, and the trend has accelerated from 1960 to the present day. The number of different 
types of substances that are used has increased considerably. In particular, the misuse of blood 
doping has become more common. In association with Tour de France in 1998, it was 
revealed extensive abuse of EPO, growth hormones, anabolic steroids and amphetamines. 
Both public authorities and sports organizations realized then that it was necessary to unite the 
forces in the fight against doping. This led to the creation of the World Anti-Doping Agency 
(WADA) 10 November 1999[4]. Its mission is to promote, coordinate and monitor the fight 
against doping in sport in all forms. WADA’s key activities include scientific research, 
education, development of anti-doping strategies, and monitoring of the World Anti Doping 
Code- the document harmonizing anti-doping policies in all sports and all countries[5]. This 
document contains the list of substances and methods that are prohibited in sports[6]. 
Doping controls are carried out at all international championships and major events to enforce 
in practice this lists of prohibited drugs, narcotics and methods. In addition unannounced spot 
checks in the training periods are also conducted. The doping analyses are performed on urine 
and / or blood samples by one of the 35 WADA approved doping laboratories around the 
world. If there is found traces of banned drugs (positive samples), the penalty is usually 
exclusion from all sports for a period of two years[4].  
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3.2 Aim of the project 
The purpose of this study is to develop an analytical method to highlight nicotine 
consumption as a doping agent.  
The first phase of this project is to identify compounds of interest for discriminate between 
the use of smoke and smokeless tobacco.  
In the second phase, an analytical method to determine concentration levels of these 
compounds of interest in urine specimens should be developed and validated. 
Then, the concentration levels of these molecules should be determined in urine specimens 
from smokers and smokeless tobacco users, in order to highlight variability due to either form 
of consumption. 
3.3 Tobacco, general background 
3.3.1 Different tobacco consumption patterns 
Tobacco is a common term for a variety of products made from dried leaves of tobacco plants 
[7]. Tobacco has two principal use patterns. Either it is smoked, or used as smokeless tobacco. 
Smoke tobacco exists in various forms as cigarettes, cigars and pipes. This kind of tobacco is 
inhaled as smoke. There are three main forms of smokeless tobacco; snus, snuff, and chewing 
tobacco. Snus is a finely ground tobacco, packaged as dry, moist, or in sachets.  
The user places a pinch or dip between the cheek and the gum. Sniffing dry snuff through the 
nose is common in some European countries.  
Chewing tobacco is available in loose leaf, plug, or twist forms, with the user putting a wad of 
tobacco inside the cheek. Smokeless tobacco is sometimes called "spit" or "spitting" tobacco 
because people spit out the tobacco juices and saliva that build up in the mouth[8]. 
 
3.3.2 The chemical components of tobacco 
The tobacco plant is a species of the nightshade family, Solanaceae, which includes numerous 
varieties. The tobacco plant is not a typically tropical or subtropical growth, it can be grown 
in temperate areas with sufficient warm summers[7]. This plant is naturally rich in a variety of 
chemical components, such as tobacco alkaloids and tobacco specific nitrosamines (TSNA). 
In addition to the chemical components found in the tobacco leaves themselves, about 600 
different additives are being added to the tobacco products during fabrication[9]. These 
additives and production methods vary from factory to factory[10]. Analyses of cigarette 
smoke have discovered over 4000 different chemical compounds[11]. About 30 carcinogens 
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have been identified in chewing tobacco and snuff. The tobacco specific N-nitrosamines 
(TSNA) and the polycyclic aromatic hydrocarbons (PAH) are among the major contributors 
to the carcinogenic activity of tobacco products[12]. 
 
3.3.2.1 Tobacco alkaloids  
Tobacco alkaloids are a large group of nitrogen-containing compounds found in plants. Many 
of them affect the central nervous system and are strong poisons, or used as drugs[13]. The 
addictiveness of nicotine is the cause of the continuing use of tobacco products. 
Nicotine is occurring to the extent of about 1.5% by weight in commercial cigarette tobacco 
and accounting for about 95% of the total alkaloid content [14, 15].  
Snus and pipe tobacco contain concentrations of nicotine similar to cigarette tobacco, whereas 
cigar and chewing tobacco have only half of the nicotine concentration of the cigarette 
tobacco[14]. 
Nornicotine, anabasine, myosmene, nicotyrine and anatabine make up for 8-12 % of the total 
alkaloid content of tobacco products. In some varieties of tobacco, nornicotine concentrations 
exceed those of nicotine[16]. 
In animals, some of these alkaloids other than nicotine are pharmacologically active, but less 
potent than nicotine. Little is known about their effects in humans [15]. 
During the production and storage some of the tobacco alkaloids are chemically converted to 









3.3.2.2 Tobacco specific nitrosamnines  
Tobacco specific nitrosamines (TSNA) are compounds exclusively formed from the 
previously mentioned tobacco alkaloids. These derivatives of tobacco alkaloids arise by the 
action of nitrous acid on nicotine, nornicotine, anabasine, and anatabine during the 
processing, fermentation and aging of tobacco. Small amounts of these compounds, also 
called N'-methyl derivatives, are found in smoke and smokeless tobacco [12, 14]. The TSNAs 




























Figure 2 Structures of tobacco-specific nitrosamines and their precursors [18]. 
 
 
3.3.2.3 Tobacco additives  
Natural herbs, spices, essences and artificial additives have been added to tobacco products 
for several years. Over 600 different additives are being added to tobacco products during 
fabrication[9]. These additives vary amongst the different tobacco products and from factory 
to factory[10].  
 
A great number of tobacco ingredients are added to enhance the natural tobacco taste and to 
give the distinctive flavour characteristics of specific products and brands[19]. Other 
substances are added to tobacco in order to prevent rapid loss of moisture. These additives are 
called moisturizers. These make the tobacco moist and preserve physical and sensory 
properties for a long time. Frequently used substances in this group are glycerol, propylene 
glycol and dietylenglycol. In order to improve the physical properties of tobacco, texturizing 
agents are added. These compounds enable tobacco products to withstand mechanical stress 
during manufacturing and transportation. Naturally occurring components such as cellulose, 
dextrin, gum, pectin and starch are commonly used. Combustion modifiers are another group 
of additives, used in cigarette paper to control the combustion properties of cigarettes. Citric 
acid and phosphoric acid are examples of such compounds.  
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In cigarette paper, adhesives are another necessity. Starch, polyvinyl acetate and certain vinyl-
based copolymers are commonly used. Last but not least, preservatives are added to protect 
the tobacco product against microbial decomposition. Relevant substances in this group are 
potassium salts of propionic acid, sorbic acid, benzoic acid and 4-hydroxsybenzoacid.  
 
The amount of additives does in some cases exceed 10 % of the weight in U.S. cigarettes, of 
which sugars, flavouring and moisturizing agents make up the majority [20]. 
 
3.4 Nicotine 
3.4.1  Pharmacological effects and doping potential 
To ensure that the initiation of this project is justified, the effects of nicotine and its potential 
as a doping agent must be addressed.  
 
If nicotine or any other substance or method shall be considered for inclusion on the 
Prohibited List of WADA at least two of the following criteria must be met: 
 
  The substance or method (alone or in combination with other substances or methods) 
has the potential to enhance sport performance,  
  the use of the substance or method represents an actual or potential health risk to the 
athlete 
 the use of the substance or method is against sports ethics[21].  
 
This must be supported by medical or other scientific evidence, pharmacological effect or 
experience. Whether or not nicotine in the form of smokeless tobacco meets these criteria is 
further discussed in this section. 
 
Most athletes avoid using cigarettes because of the negative physiological effects of smoking. 
Smoking impairs performance by causing airway constriction, additionally the carbon 
monoxide in smoke combines with haemoglobin, making less haemoglobin available for 
oxygen transport, resulting in a decreased  maximal oxygen uptake for heavy smokers[22]. 
Thus, professional athletes rarely smoke tobacco. 
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The prevalence of smokeless tobacco use amongst athletes is suspected to be high in certain 
sports on the other hand. Participants in team sports were remarkable smokeless tobacco users 
already in the 1980s, especially ice hockey and floor ball players. By the mid 1980s and early 
1990s the prevalence of smokeless tobacco use among professional baseball players was 
about twice high that of the general population of males in the same age range. In the early 
90s it was estimated that about 45 % of the premiere professional athletes in USA were using 
smokeless tobacco[23]. In 2003 the prevalence was still high, with 30–36% of the major 
league players reporting regular use[24]. Without doubt, smokeless tobacco use is popular 
amongst athletes, and incidences of smokeless tobacco use in athletics are likely to increase in 
parallel with the expanded use in society as a whole[25].  This trend could be explained by the 
athletes’ repulsion of cigarettes, but there is some evidence supporting nicotine might be 
performance enhancing. 
 
Nicotine action is mediated trough the nicotinic acetylcholine receptors. These receptors 
respond endogenously to acetylcholine in the periphery and central nervous system. Nicotine 
acts on these receptors and cause neuronal excitation.  
 
The peripheral effects of nicotine are mainly caused by the excretion of catecholamine, such 
as adrenaline and noradrenaline from the medulla. When reaching receptors in heart and lung 
tissues, the catecholamine’s causes cardiovascular effects. These effects consist of an increase 
in pulse rate and blood pressure and mobilisation of blood sugar and fatty acids [26]. 
Repeated exposure leads to development of tolerance to these effects, thus other mechanisms 
are more likely responsible of the performance enhancing capacities of nicotine.  
 
It is suggested that nicotine might prolong endurance by a central mechanism that involves 
nicotinic receptor activation and/or altered activity of dopaminergic pathways[27]. This was 
demonstrated by a study of nicotine administration on exercise endurance. A significant 
improvement in performance was observed, with ten out of twelve subjects being able to 
cycle for a longer period with nicotine administration (17% ±7%, P<0.05)[27]. Additionally, 
nicotine is reported to improve coordination and produce faster motor responses[28]. These 




Evidence is presented supporting the involvement of nicotinic acetylcholine receptors in 
relieves of anxiety[29]. As well as reducing anxiety, nicotine is reported to cause increased 
cognitive performance, arousing and alertness. These beneficial effect on mental capacity, has 
been demonstrated by a  reduced stress-related decline in performance after nicotine 
consumption[26, 30] [29]. In sports like ski jumping, where control of the nerves is essential; 
use of nicotine could provide a considerable advantage.   
 
Another effect of nicotine is weight loss associated with serotonin release[28]. In sports 
competing in weight categories such as different martial arts, a lower bodyweight would be 
beneficial. As well in many endurance sports lowering the bodyweight could be 
advantageous.  
 
The suspicion about the doping potential of nicotine is confirmed by another study in which 
baseball players using smokeless tobacco were asked about the reason for their tobacco use. 
This study revealed use of smokeless tobacco because it helped them to relax. Players 
reported smokeless tobacco use as a coping strategy, or as a concentration or weight control 
aid, and some even believed that it helped to improve their field performance[24]. 
 
If nicotine has the potential to enhance performances, use of smokeless tobacco enables the 
athletes to benefit of them without most of the harmful effects associated with smoking.  
If this is the case, nicotine may be used with the intention of artificially enhancing physical or 
mental capacities. The intentional use of a substance in order to enhance performance is 
defined as doping, and would violate the spirit of sports. 
This evidence suggests that nicotine could meet one of the previously mentioned WADA 
criteria for inclusion of new substances and methods on the Prohibited List[21]. 
 
As previously mentioned, smokeless tobacco is associated with less risk than cigarettes; 
however the risk is still appreciable. A systematic review of the relation between smokeless 
tobacco and cancer in Europe and North America addressed the risk of developing pancreatic 
cancer. In this case, the authors concluded that the overall data suggest a possible indication 
that "smokeless tobacco" use increases the risk of developing pancreatic cancer[31]. Other 
published studies also support these findings [32, 33]. 
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Snus has also been blamed for increasing the risk of developing a number of other cancers 
such as prostate, biliary cancer, bladder cancer, kidney cancer, larynx cancer, nasal cancer, 
haematopoietic and lymphoid cancers, however, more evidence is needed before one can deny 
or confirm this hypothesis[31]. There are as well great uncertainties concerning the potential 
risks for cardiovascular events associated with snus use. A systematic review concluded that it 
seems possible that there is a moderate risk of cardiovascular disease associated with the use 
of snus[34].  
 
This opens for the discussion whether or not nicotine, meets the second criteria for inclusion 
on the Prohibited list; that the use of the substance or method represents an actual or potential 
health risk to the athlete[21].  
 
If a substance meets two of the previously mentioned criteria, it should be considered for 
addition to WADA’s “Prohibited List of Substances and Methods”. However, lack of 
prevalence data on use and means to distinguish between smoke and smokeless tobacco 
consumptions is the main reason nicotine has not been considered for addition to this list. 




3.4.2 Absorbtion and metabolism 
Nicotine is a weak base with a pKa around 8.0, but the presence of both a pyrrolidine and 
pyridine nitrogen give nicotine dibasic properties. At pH lower than 2.7,  nicotine exists in the 
diprotonated form (two charges), at pH ranges from 4.5 to 7.0 it is dominated by the 
monoprotonated form (1 charge), and at pH above 7.0 nicotine is mostly neutral[35]. 
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Figure 3 Illustration of the pH dependent absorbtion of nicotine 
 
 
The rate of nicotine absorbtion through the biological membranes is a pH dependent process 
because unionised organic bases are lipophilic (fat soluble) while ionized organic bases are 
hydrophilic (water soluble). By increasing the amount unionised nicotine in relation to ionized 
nicotine, the physiological effects of nicotine are enhanced[19]. 
 
In tobacco smoke, the pH is acidic (about 6). As a consequence, only a negligible amount of 
nicotine is absorbed from the mucous membranes in the mouth because less than 1% of 
nicotine is unionised (free). By increasing the pH of smoke tobacco, the amounts of free 
nicotine are increasing. At pH 8.0, the amount of free nicotine is increased to approximately 
50%.  The main routes of nicotine absorbtion in smokers who inhale, are trough the alveoli of 
the lungs. When tobacco smoke reaches the small alveoli of the lung, nicotine is rapidly 
absorbed independently of smoke pH. This is presumably because of the huge surface area of 
the alveoli and small airways, which facilitate transfer across cell membranes.  
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The oral bioavailability of nicotine is about 45 %. Bioavailability is incomplete because of 
first pass metabolism. The nicotine absorbtion through the gastrointestinal tract is poor 
because of the acidic nature of the stomach juice, but is well absorbed in the small intestine, 
which has a more alkaline pH and a larger surface area[16, 26]. Snus and nicotine-containing 
medications are buffered to alkaline pH, thus absorbtion of nicotine through the oral mucosa 
is facilitated[19]. 
 
After absorbtion, nicotine enters the bloodstream and is distributed to body tissues. The 
plasma half life of nicotine after cigarette smoking averages about 2 hours because of the 
extensive metabolism of nicotine[14]. The nicotine metabolic pathway is complex and 
involves the formation of a number of Phase I metabolites through oxidation, hydroxylation 
and N-demethylation, and, also Phase II metabolites through conjugation with glucuronic 
acid[36] There are evidence of interindividual differences in nicotine metabolism. 
Polymorphism of the CYP 2A6 gene has a major impact on nicotine clearance. Gender-
related effects, disease states, and various inhibitors and inducers affect individual rates of 
nicotine metabolism[14]. Quantitative aspects of the pattern of nicotine metabolism have been 
elucidated in humans. About 90% of a systemic dose of nicotine can be accounted for as 
nicotine and nicotine metabolites in urine[14] In average, 75% of the nicotine dose is 
converted to cotinine, which in turn is also extensively metabolized. About 10-15% of this 
cotinine dose is excreted unchanged in urine. The remainder is converted to other metabolites, 
mainly trans-3-hydroxycotinie [14, 16]. Nicotine, cotinine and trans-3-hydroxycotinieare all 
subjected to Phase II metabolism and are transformed to their respective glucuronide acid 
conjugates (See Figure 4). In most smokers, nicotine and these five metabolites constitutes > 
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Figure 4 Primary routes of nicotine metabolism [25] 
 
3.5 Choosing Biomarkers for tobacco exposure 
In order to develop a method with sufficient discriminating power to distinguish between 
different tobacco consumption patterns, compounds of interest must be identified.  
This molecule should meet following requirements on its own or paired with other molecules;  
 tobacco specific, not measurable in significant amounts after exposure from other 
sources 
 specific to a particular form of tobacco 
 present in sufficient amounts to be detected in body fluids, preferentially urine  
 
In addition, it would be beneficial if the compound was not metabolically derived from 
nicotine. This would be necessary in order to differentiate between nicotine from tobacco and 
nicotine containing medicine.  
 
The amount of the different chemical compounds measured in body fluids will vary 
depending on the formulation of the tobacco product and their pharmacokinetic properties. 
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In the following sequences, different strategies of choosing these compounds will be 
considered. From this section on, these compounds are referred to as biomarkers.  
 
 
3.5.1 Major tobacco alkaloids  
A better strategy would be to have a closer look at the composition of the tobacco plants. This 
would greatly enhance the chances of finding a tobacco selective biomarker.  
In general the presence of the tobacco alkaloids in human tissues can be attributed to use of 
tobacco products[11]. Though low levels of nicotine have been found in tea and edible plants, 
nicotine derived from dietary sources is insignificant compared with the amounts derived 
from tobacco use [11, 38]. Concentrations of nicotine and its metabolites in biological fluids 
are frequently used to ascertain whether or not a person is using tobacco and to estimate 
nicotine intake [15]. Because nicotine is almost extensively metabolized only a small 
percentage is excreted unchanged in urine (See section 3.4.2). Analysis of nicotine alone in 
biological samples can provide insufficient information due to its short half-life and the 
dependency of the analytical result on the time of sampling. Therefore it would be more 
useful to test for nicotine metabolites which have longer half-lives and detection windows 
compared to nicotine[36]. Cotinine and trans-3’-hydroxycotinine have longer half-lives and 
are therefore considered as potentially more useful biomarkers for the assessment of exposure 
to nicotine[36]. 
The ratio of nicotine:cotinine in urine of smokeless tobacco users and cigarette smokers 
showed a significant difference between groups in one study [38].This is a good indication 
that it might be possible to distinguish between consumption of the different tobacco products 
when comparing the ratio of these metabolites in urine samples. In most smokers, 
measurements of urinary nicotine, cotinine, trans-3-hydroxycotinine and their respective 
glucuronic acid conjugates accounts for more than 80 % of the absorbed nicotine dose[37]. 
Therefore nicotine and these 5 metabolites are of great interest as biomarkers in this project, 
(Figure 4). Because the glucuronic acid conjugate requires a more sophisticated and time 




However, nicotine and its metabolites are present in nicotine-containing medications to 
various degrees. Discrimination between nicotine from smoke, smokeless tobacco and 
nicotine containing medication using only these biomarkers is probably insufficient.  
 
3.5.2 Minor tobacco alkaloids  
Minor alkaloids are present in tobacco, but not in nicotine-containing medications. 
In most tobacco strains, nornicotine and anatabine are the most abundant of the minor 
alkaloids, followed by anabasine. This order of abundance is the same in cigarette tobacco 
and oral snuff, chewing, pipe and cigar tobacco. Nornicotine levels are the highest in cigar 
tobacco, and anatabine levels are lowest in chewing tobacco and oral snuff [14]. Anabasine as 
a percentage of the total alkaloids was significantly lower in oral snuff than in cigarette and 
pipe tobacco [15]. The low levels of anabasine in oral snuff are due to the conversion to N-
nitrosanabasine and/or other degradation [15, 17]. Urine levels of the minor alkaloids are 
shown to correlate well with systemic nicotine intake from various tobacco products and 
could be useful to determine the origin of nicotine [15]. Urinary anabasine can be used as a 
biomarker of tobacco use to monitor compliance to nicotine therapy. Patients abstaining from 
tobacco typically use to have a urinary anabasine concentration < 2 μg/L. The mean anatabine 
concentrations in urine of cigarette smokers (22ng/ml) were about half those found in urine of 
smokeless tobacco users(41-45ng/ml), despite similar nicotine and cotinine levels, and 
although smokeless tobacco products contain considerably lower levels of anatabine than 
cigarette tobacco. A likely explanation is that anatabine is decomposed to a much greater 
extent than is nicotine in burning tobacco, resulting in lesser absorbtion by cigarette smokers 
than by smokeless tobacco users [38]. In subjects abstaining from tobacco but using nicotine 
gum, anabasine and anatabine levels have been found to be below the cut off point of 2 
ng/mL[38]. This makes the minor tobacco alkaloids promising as biomarkers to distinguish 
between smoke and smokeless tobacco, as well as the use of nicotine containing medications. 
 
3.5.3 Tobacco specific nitrosamines 
The total amount of the TSNAs; NNN, NAT, and NAB, were significantly higher in urine of 
smokeless tobacco/snus users compared to smokers[39]. Daily exposure to tobacco-specific 
nitrosamines is estimated to about 20 μg in smokers and 68 μg in smokeless tobacco users. 
This is presumably due to the conversion of tobacco alkaloids into nitrosamines during the 
manufacturing and storage of smokeless tobacco products [15] (See Figure 5). Comparative 
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studies have generally shown lower levels of tobacco-specific nitrosamines in Swedish snus 
than in similar products sold on the American continent[32].  Because of the considerable 
differences in the concentration of the nitrosamines in the different brands of snus the 
nitrosamines are less promising as biomarkers. Therefore these compounds were not further 
investigated. 
3.5.4 Tobacco additives as biomarkers 
One possibility to discriminate between nicotine from smoke and smokeless tobacco could 
theoretically be based on differences in additives used during the manufacturing of the 
tobacco products. Due to legal requirements, any tobacco company that sells cigarettes in a 
European country must submit a list of additives to the Department of Health in the current 
country. A serious attempt to get access to this complete list of the chemical composition of 
the different tobacco products in Norway was performed. The tobacco industry considers 
these additives as a trade secret, and prohibits anyone who views the lists from sharing the 
content with external toxicologists or others, therefore this request was denied.  
In 1994, a list of the 599 additives used in the manufacture of cigarettes by the five major 
American cigarette companies was published[9]. This list does not specify which compounds 
are used in the different brands and makes it impossible to identify ingredients common to 
one type of tobacco product.  
Many of these substances are expected to be transformed formed during heating and / or 
combustion as well[19]. This would further complicate the use of additives as biomarkers. 
In addition, most of the tobacco additives are used in the manufacture of cigarettes and other 
tobacco products approved for use by the FDA GRAS list[20]. This would mean that most of 
the additives are commonly used in food and commercial products; thereby their specificity as 
biomarkers to tobacco exposure is most likely insufficient.  
Therefore neither tobacco additives were selected as biomarkers in this project. 
 
3.5.5 The selected biomarkers 
In order to develop a relatively time and cost efficient sample preparation step with a high 
discriminating potential, the following compounds were chosen to investigate their potential 
as biomarkers to distinguish between smoke and smokeless tobacco use: 
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 nicotine (major tobacco alkaloid) 
 cotinine (nicotine metabolite, major tobacco alkaloid) 
 trans-3-hydroxycotinine (nicotine metabolite, major tobacco alkaloid) 
 anatabine (minor tobacco alkaloid) 
 anabasine (minor tobacco alkaloid) 
 nornicotine (minor tobacco alkaloid as well as nicotine metabolite) 
 
Table 1 Concentration of the selected biomarkers expected to be measured in urine [15-17, 38, 40] 
Expected urinary concentration levels (ng/mL):  
  low medium high non tobacco user   
nicotine 2 250 1000 < 20  
cotinine 2 375 1500 <20  
trans-OH-cot 10 625 2500 <50  
anatabine 2 50 200 <2  
anabasine 2 50 200 <2  
nornicotine 2 50 200 <15   
 
 
3.6 Basic principles of the analytical procedure 
3.6.1 Sample preparation 
Urine is often the body fluid of choice for human exposure assessment due to a broad 
detection window and relatively non-invasive aspect of sample collection[41]. Urine is an 
aqueous solution consisting of mostly water, and about five percent metabolic wastes such as 
urea, dissolved salts, and organic compounds. In humans, all the water soluble wastes are 
excreted by the kidneys, highly diluted in the form of urine. The sample preparation step 
allows isolation of the compounds of interest and adequate up-concentration necessary in 
order to reach the limit of detection looked for. 
 
3.6.1.1 Solid phase extraction (SPE) 
In solid phase extraction the analytes are being retained on a sorbent that contains different 
functional groups depending on the type of column. As the solution pours trough the column, 
the analytes are being retained by strong interactions with these groups on the surface of the 
sorbent. The general setup for any SPE procedure consists of four steps: (1) conditioning the 
SPE material by means of methanol or acetonitrile to rise the functional groups, followed by 
water to remove the organic solvent form the cartridge, (2) application of the aqueous 
 24 
biological sample to the SPE material, (3) removal of interferences by a washing step, and (4) 
eluting the analytes. The most widely applied packings are based on silica or chemically-
modified silica. On these C18 – or C8-materials, the analyte retention is based on 
hydrophobic interactions. Another popular packing is copolymers in mixed mode materials, 




Figure 5 Schematic diagram of a solid-phase extraction procedure[1] 
 
 
3.6.2 HPLC (High performance liquid chromatography) 
Chromatography is a physical separation method in which the components to be separated are 
selectively distributed between two immiscible phases: a mobile phase flowing through a 
stationary bed. In liquid chromatography, this mobile phase is a liquid[42]. High performance 
liquid chromatography is basically a highly improved form of column chromatography where 
the solvent is being forced through the column under high pressures, which allows the use of 
smaller particle size for the column packing material. This provides faster and better 
separation of the analytes. The column is a steel tube filled with fine-diameter packing 
material. Liquid chromatography columns are typically 100-300-mm long and have an 
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internal diameter of 3-4.6 mm. The mobile phase is pumped from a bottle, trough an injector, 
into the column, and out to the detector. Before injection to the column, the sample should be 
dissolved in the mobile phase or a similar solvent. When injected, the sample flows with the 
mobile phase trough the column[42]. The chromatographic process occurs as a result of 
repeated sorption/desorption steps between the liquid phase and the stationary phase, during 
the movement of the analytes along the stationary phase. Figure 6 illustrates the intra- and 
intermolecular interactions between analyte molecules and mobile and stationary phase 
important in sorption/desorption.  
 
HPLC can be divided into two categories depending on the relative polarity of the solvent and 
the stationary phase: Normal phase and Reversed phase. 
 
In Normal phase HPLC, the column is filled with tiny silica particles, and the solvent is non-
polar. Polar compounds in the mixture are tighter retained to the polar silica than non-polar 
compounds when eluting through the column. Therefore non-polar compounds will elute 
more quickly from the column[43]. 
 
Reversed phase HPLC is the most applied form of HPLC. By attaching long hydrocarbon 
chains to the surface of the silica, the columns are modified to become non-polar. Frequently 
used are the silica C18 columns, containing hydrocarbon chains with 18 carbon atoms. When 
a polar solvent is used, strong attractions between the polar solvent and polar molecules in the 
mixture will occur. Spending most of their time moving with the solvent, the polar molecules 
are less retained will elute from the column first[43].  Non-polar compounds in the mixture 
will tend to form attractions with the hydrocarbon groups because of Van der Waals 
interactions (Figure 6).  
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Figure 6 Various functional groups bound to the silica surface and various interaction between theese 
groups and different analytes[42]. 
 
The time taken for a particular compound to travel through the column to the detector is 
known as its retention time. This time is measured from the time at which the sample is 
injected to the point at which the analyser measures maximum peak intensity for that 
compound. Different compounds have different retention times. For a particular compound, 
the retention is influenced by the nature of the stationary phase, the eluent/solvent 
composition and pH together with the column temperature[42].   
 
 
3.6.3 Mass analyser (ESI-MS/MS) 
 
The separated analytes enter the mass spectrometer via the electrospray source. The eluent 
from the HPLC is nebulized into small droplets by a combined action of a strong electric 
potential between needle and counter electrode, and a high speed concurrent N2 flow. This 
results in small droplets with an excess charge (positive or negative depending on the 
operation mode of the ion-source.)  In their flight between the ESI needle and the ESI source 
block, neutral solvent molecules evaporate from the droplet surface. As a result, the droplet 
size decreases. This reduces the distance between the excess charges at the droplet surface. 
After some time, the surface tension of the liquid can no longer accommodate the increasing 
Coulomb repulsion between the excess charges at the surface.  At this point, a Coulomb 
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explosion (Figure 9) leads to disintegration of the droplets. This process may be repeated a 
number of times, leading to smaller and smaller offspring droplets. Eventually gas phase ions 







Figure 8 Electron spray ion source, reprinted with permission from Terje Wasskog 
 
The mass spectrometer basically consists of five parts: sample introduction, ionization, mass 
analysis, ion detection, and data handling[42]. 
 
After the ions have been produced, separation and filtration according to their mass-to-charge 
(m/z) is performed on a mass analyser. Most commonly used for mass analysis, is the 
quadrupole mass filter. This mass analyser consists of four hyperbolic or cylindrical rods that 
are placed in parallel in a radial array. Opposite rods are charged by a positive or negative 
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Figure 7 Illustration of the mechanism of Electron spray ionization [1] 
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direct current potential at which an oscillating radiofrequency alternating-current voltage is 
superimposed. Ions are introduced into the quadrupole filter, and begin to oscillate in a plan 
perpendicular to the rod length as they traverse trough the quadrupole filter. At a given 
combination of direct-current and alternating current applied to the rods, the trajectories of the 
ions of one particular m/z are stable, and are transmitted towards the detector. Ions with other 
m/z do not pass the filter because of their unstable trajectories, and are discharged on the rods 
and lost in the vacuum system[42]. Triple stage quadrupole (TSQ) system was designed to 
cleave ions into their daughter ions. Use of this triple quadrupole system allows so-called 
MS/MS analysis. 
The triple-quad system consists of a scanning (Q1) quadrupole analyser for separating the 
original ion(s), an unscanned quadrupole that serves as a collision cell to fragment the ions 
sent to it by collision with a heavy gas molecule, and a scanning (q) quadrupole(/hexapole) 
that can separate the fragments produced in the (Q2) unit[43]. (Figure 9) 
 
Figure 9 Triple quadrupole system, reprinted with permission from Terje Wasskog 
 
The mass analyser system used in this project, a linear ion trap quadrupole (LTQ), is a square 
array of precision-machined and precision-aligned hyperbolic rods. Each rod is cut into three 
sections. Ions are ejected during scan out trough the center section rods. Quartz spacers act as 
electrical isolators between adjacent rods. The four rods of each section can be considered to 
be two pairs of two rods each. Application of voltage to the rod pairs produces a two 
dimensional quadrupole field with the mass analyser cavity which drives ionic motion in the 




Figure 10 Linear ion trap quadrupole (LTQ) rod assembly [44] 
 
Mass spectrometry can be performed in two general data-acquisition modes: full-spectrum 
analysis, where a series of mass spectra is acquired, and selected-ion monitoring (SIM), where 
the ion abundances of preselected ions are acquired. In quadrupole instruments, acquisition 
SIM mode provides a substantial gain in signal-to-noise ratio(S/N)[42, 43]. The following 
four different MS/MS operating modes exist: 
Table 2 MS/MS operating modes 
Q1 Q2 Technique 
SIM Scan MRM 
SIM SIM Product ion scan 
Scan SIM Parent ion scan 




An LC/MS system is an HPLC pumping system, injector and column coupled to a mass 
spectrometer through some type of evaporating ionizing interface (ESI). A computer system 
coordinates the components of the system together by providing control of the HPLC for 
flow, solvent gradient and remote starting of injection and the gradient run. It also provides 
control of the ion source parameters, mass spectrometry scan range and lens in addition to 
access and process data from the ion detector amplifier. The digital data is then processed by 
the computer software to provide a total ion chromatogram and the molecular weights of the 
compounds in the peaks detected using mass spectrometer’s spectral data[42, 43]. Coupling 





Figure 11 Overview triple quadruple-MS, Reprinted with permission from Terje Wasskog, the Finningan 








3.7 Method validation 
Bioanalytical method validation includes all of the procedures that demonstrate that a 
particular method used for quantitative measurements of analytes in a given biological matrix 
is reliable and reproducible for its intended use. This following section is a brief presentation 
of important parameters of such a validation process. 
The precision of an analytical method describes the closeness of individual measures of an 
anlayte when the procedure is applied repeatedly to multiple aliquots of a single homogenous 
volume of biological matrix. In order to meet both FDA [45] and IHC[46] guidelines, 
precision should be measured using a minimum of 9 determinations over a minimum of 5 
concentrations levels covering the specified range. The precision determined at each 
concentration level should not exceed 15% of the coefficient of variation (or 20% for the 
LLOQ). Precision is subdivided into estimates of repeatability (CVr), and intermediate 
imprecision (CVR). Repeatability expresses the precision within the same run, while 
SPE HPLC ESI MS/MS 





intermediate imprecision express precision between measurements performed in different 
days. Precision is for both categories expressed as RSD, relative standard deviation (%). 
 
Trueness, is described as the closeness of agreement between the average value obtained from 
a large serious of test results and an accepted reference value. The measure of trueness is 




Figure 13 Illustration of validation parameters, trueness 
 
 
The accuracy of an analytical method describes the closeness of mean test results obtained by 
the method to the true value of the analyte. Accuracy is determined by replicate analysis of 
samples containing known amounts of the analyte. Accuracy should be measured using a 
minimum of 5 determinations per concentration. A minimum of 3 concentration in the in the 
expected concentration range is recommended by the FDA[45] ICH, on the other hand 
suggests a minimum of 9 determinations over a minimum of 3 concentration levels covering 
the specified range[46]. The mean value should be within 15% of the actual value (20% for 
LLOQ). The deviation of the mean from the true value serves as the measure of accuracy. 
Accuracy is defined as the percent relative error (%RE) and was calculated using the 
following formula %RE = (E − T)(100/T) where E is the experimentally determined 
concentration and T is the theoretical concentration[45] 
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Figure 14 Illustration of validation parameters, accuracy 
 
The linearity of an analytical procedure is its ability to obtain test results which are directly 
proportional to the concentration (amount) of analyte in the sample. Method linearity should 
be determined concurrently during the accuracy study. Correlation between recalculated 
values and theoretical values, expressed as y = ax + b, y is the recalculated values, x is the 
slope of the curve, x is the theoretical values and b is the value where the curve crosses the y 
axis. Slope values should be as close to 1 as possible, and R
2
 values above 0,995, for the 
method to be considered linear and valid over the selected range. The measured values should 
be as close as possible to the theoretical values[45].  
The true performance of the method-bias and precision are unknown. The experiments 
performed during the validation phase will only provide estimates of bias and precision. How 
reliable those estimates are depends on the experiments. Design and sample size have to be 
carefully chosen in order to obtain reliable estimates.  
Detection limit (LO ) is the lowest amount of analyte in a sample which can be detected but 
not necessarily quantitated as an exact value[46]. 
 
Quantitation limit (LOQ) is the lowest amount of analyte in a sample which can be 
quantitatively determined with suitable precision and accuracy. The quantitation limit is a 
parameter of quantititative assays for low levels of compounds in sample matrices, and is used 
particularly for the determination of impurities and/or degradation products [46]. 
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Selectivity is defined as the ability of a method to differentiate an analyte in the presence of 
other components in the sample. Selectivity should be assessed by analyzing at least six 
sources of blank samples of appropriate matrix. Each blank should then be tested for 
interference and selectivity should be established at the LOQ[45]. 
 
The recovery of an analyte in an assay is the detector response obtained from an amount of the 
analyte added to and extracted from the biological matrix, compared to the detector respons 
obtained for the true concentration of the pure standard. Recovery pertains to the extraction 
efficiency of an analytical method within the limits of variability. Recovery of the analyte 
need not be 100%, but consistent, precise and reproducible. Recovery experiments should be 
performed by comparing the analytical results for extracted samples at three concentration 
levels (low, medium and high) with unextracted standards that represents 100% recovery. 
 
Stability of the analyte in biological matrix at intended storage temperatures should be 
established. The influence of freeze-thaw cycles should be tested by a minimum of 3 cycles at 
2 concentrations in triplicate[45]. 
 
4 EXPERIMENTAL 
4.1 Reagents and chemicals 
 
Nicotine, cotinine, anabasine and anatabine and were purchased from Sigma-Aldrich 
(produced by Fluka).  Trans-3’-hydroxycotinine and anatabine were obtained from Toronto 
Research Chemicals. The internal standards (R,S)-Anatabine-2,4,5,6-d4 and Trans-3’-
hydroxycotinine- methyl-d3 were purchased from Toronto Research Chemicals, whereas 
Nicotine-D4 was supplied by LGC Standards, (produced by Cerillant) and Cotinine-D3 was 
supplied by Prochem, (produced by Cerillant). Methanol (> 99, 9%) was obtained from Merck 
Chemicals (Darmstadt, Germany). Acetonitrile HPLC (> 99, 9%) was purchased from 
Biosolve Chemicals (Valkenswaad, Netherlands). Ammonium hydroxide (>25 %) was 
supplied by Sigma-Aldrich (prodused by Fluka Analytical) 
KH2PO4(99.5-100.5 %) , Na2HPO4 (>98 %) and HCl( >37 %) fuming was purchased from 
Sigma-Aldrich (St. Louis, USA). Formic acid was supplied by Sigma-Aldrich, produced by 
Fluka Analytical. NaOH pellets (>99 %) was purchased from VWR International (Leuven 
Belgium).  Liquid nitrogen TP 100 and Helium (99%) Alphagaz-HE (collision gas) was 
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supplied by Carbagas(Domididier, Switzerland). The nitrogen gas was produced by the N2-
Mistral-Ofrom DBS nitrogen generator. Purchased from Analythical Instrument (Vigonza, 
Italy). All chemicals and reagents were HPLC grade (≥99% purity)  
Ultrapure water was produced by a Milli-Q Gradient A10 water purification system with a Q-
Gard
®
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4.2 Material and equipment 
The LC-MS/MS system used for the assay comprised a Rheos 2000 CPS-LC system pump 
(Flux Instrument, Basel, Switzerland) and a HTS Pal autosampler (CTC analytics AG, 
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Zwingen, Switzerland) coupled to a linear ion trap mass spectrometer LTQ-MS 
(ThermoFinnigan, San Jose, CA, USA), equipped with an atmospheric pressure 
ionisation(API) interface, Ion MAX™. Mass spectrometric analysis was conducted using a 
Quattro Premier XE™ triple quadrupole mass spectrometer (Waters 
®
 Corporation, Milford, 
MA) with MassLynx™ v 4.1 software. The separation was performed on a Luna® HILIC 
Phenomenex 150 x 2.0 mm column with 3 µm particles, 200 Å pore diameters. 
For evaporation of the samples, a Pierce ReactiVapTM III Evaporator with 24 ports, 
(Pierce&Rochford, USA) was used. For centrifugation a Multifuge 3S from Thermo electron 
corporation (Osterode, Germany) or a Heraeus Multifuge 3S+ from Thermo Scientific 
(Osterode, Germany) was used. Oasis
® 
HLB (1cm3 x 30 mg) SPE cartridges was obtained 
from Waters Corporation (Milford, MA, US) Visiprep
TM
 24 was used for extraction of all the 
samples prepared by SPE, and the vacuum pump used was a KNF neuberger vacuumpump 
(Balterswil, Switzerland). 
 
4.3 Sample preparation and extraction 
One ml urine sample and 1 ml phosphate buffer (0. 2 M, pH 7) were transferred into a tube 
and 10 µL of a 10ng/mL internal standard solution was added. The samples were centrifuged 
for 10 min at 3500 rpm.  
The Oasis HLB (1cm
3
 x 30 mg) SPE cartridges were conditioned with 1.0 ml of methanol, 1 
ml of H20 prior to loading with 2 ml of buffered sample solution.  
1 ml of 2% NH4OH/H2O solution was used to rinse the cartridges prior to eluting with 1 mL 
MeOH. 
Extracts were collected in conical tubes and evaporated carefully to dryness under a stream of 
air at 50 °C. Extracted urine residues were reconstituted in 500μL of a solution of the HPLC 
mobile phase constituents’ acetonitrile and formate buffer (0.1 M, pH 3) in 90:10 (v/v), and 
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Transferring sample into microvials  
500 µl of 5 % NH4OH in CH3OH  
 
 
Figure 16 Extraction method used on Oasis HLB cartridges 
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4.4 Liquid chromatography- tandem mass spectrometry conditions 
 
For the chromatographic separations, 0,1M ammonium formate buffer, pH 3 and acetonitrile 
were used as mobile phase with the following gradients: 







Flow rate                    
(µl/min) 
0 0 2 98 250 
1 3 2 98 250 
2 7 65 35 250 
3 10 65 35 250 
4 11 2 98 250 
5 13 2 98 250 
Solvent A: Formiate buffer pH 3 
Solvent B: Acetonitrile 
 
Before every set of analyses a conditioning step was performed at a flow rate of 250 μL 
min−1 for 10 min, the injected volume was 10 μL. The column and the autosampler tray 
temperatures were set at 30 °C and 4 °C, respectivley. 
The mass spectrometer was operated in positive ESI mode. One MRM transitions was 
monitored for each analyte. MS operating conditions were set as follow: spray voltage= 5.0 
kV; heated capillary voltage and temperature of 10V and 320°C, respectively; ionization 
width of 1.5 Da; activation time= 30 ms; activation q of 0.250 and scan time was fixed at 30 
ms. Sheath gas, auxiliary gas and sweep gas (nitrogen) were set at 20, 5 and 1,5 respectively. 
Analyte-specific normalized collision energies, MRM transitions and retention times are 
provided in table 5. 










Nicotine 3.38 0.19 25 163.10 → 132 
Nicotine-d3 3.39 0.04 25 167.10 → 134 
Cotinine 2.19 0.01 28 177.10 → 98 
Cotinine-d3 2.16 0.18 28 180.10 → 100 
Trans-OH-cot 2.36 0.01 26 193.10 → 134 
Trans-OH-cot-d3 2.37 0.01 26 196.10 → 134 
Anatabine 5.28 0.15 23 161.10 → 144 
Anatabine-d4 5.3 0.14 23 165.10 → 148 
Anabasine 6.21 0.16 25 163.10 → 146 
Nornicotine 7.03 0.07 26 149.10 → 132 
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4.4.1 Method Validation 
4.4.1.1 Collection of anayte free urine  
Analyte-free urine used in method development and validation was collected from nicotine-
abstinent members of the Swiss anti doping laboratory, unexposed to environmental smoke 
the last 48 h. 
For the quantitative validation, urine samples were collected from two individuals at 9 am of 
the initiation day. The urine was merged in one bottle, stored in the fridge and used during the 
following days of the validation. 
4.4.1.2 Choice of internal standards 
As internal standard the deuterated standards of nicotine, cotinine, trans-3-hydroxycotinie and 
anatabine, respectively nicotine-d4, cotinine-d3, trans-3-hydroxycotinie -d3 and anatabine-d4 
were purchased. These are presented with structural formulas in Table 16.  
When calculating the peak area ratios, the peak area of the standard was divided on the peak 
area of the respective internal standard. The internal standard was not available for the 
compounds anabasine and nornicotine, thus anatabine-d4 was used as refrence standard for 
these two analytes as well. Since anatabine, anabasine and nornicotine have quite similar 
chemical properties, it was defendable to use anatabine-d4 as internal standard for anabasine 
and nornicotine as well. 
4.4.1.3 Assessment of specificity 
The specificity of the method was assessed by the analysis of analyte-free urine samples from 
six individuals. All individuals were nicotine abstinent and non-exposed to significant 
amounts of environmental smoke the last 48 hours. The urines were collected from both males 
and females, all personnel within the Swiss anti doping laboratory. In addition, urine of one 
child was analysed as well. Each sample was treated according to the developed method to 
highlight the absence of interfering peaks observed at the retention times for nicotine, 
nicotine-d3, cotinine, cotinine d-3, trans-3-hydroxycotinie, trans-3-hydroxycotinie -d3, 
anatabine, anatabine-d4, anabasine and nornicotine. For each individual urine, following 
analysis were performed; one analysis of pure (analyte free) urine, a second analysis of pure 
urine spiked with 100 ng/mL of the respective IS. And a third analysis of pure urine spiked 
spiked with100ng/mL of anabasine and nornicotine standards, since their respective internal 
standards were not available. In total18 urine samples were extracted and treated to assess the 




4.4.1.4 Quantitative analysis 
Quantitative analysis was performed for all the selected biomarkers within the range of 10 to 
10000 ng/mL for nicotine, cotinine and trans-3-hydroxycotinie, and the range of 10 to 500 
ng/mL for anatabine, anabasine and nornicotine.  
The calibration process was performed over three days. Calibration standards at two 
concentration levels (k=2) and validation standards at three concentration levels (k=3) were 
prepared in triplicate (n=3) for each day. Concentrations levels of the calibration and 
validation standards are given in Table 6. 
 






Nicotine 10, 10000 10, 5000, 8500 
Cotinine 10, 10000 10, 5000, 8500 
Trans-OH-cot 10, 10000 10, 5000, 8500 
Anatabine 10, 500 10, 250, 400 
Anabasine 10, 500 10, 250, 400 
Nornicotine 10, 500 10, 250, 400 
 
Calibration curves for each analyte were plotted with peak ratio values of analyte peak area 
over internal standard peak area. Estimates of trueness, repeatability and intermediate 
precision were calculated at each concentration level. Trueness was expressed in percent as 
the closeness of agreement between the average concentration obtained from the 
measurements and the theoretical concentrations. Assessment of precision was performed by 
calculating repeatability (CVr), expressed the precision within the same run, and intermediate 
imprecision express as precision between the measurements of different days. Both 
repeatability and intermediate precision was expressed in percent as relative standard 
deviation (RSD).  
 
 
4.4.2 Method application to snus and cigarette samples 
The present analytical procedure was applied for the determination of nicotine, cotinine,   
trans-3-hydroxycotinie, anatabine, anabasine and nornicotine in urine of one smoker (female) 
and one snuser (male). Both volunteers had been nicotine deprived over night.  
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The first urine sample was collected one hour after consuming of one unit of the respective 
tobacco product. The next three urine samples were collected throughout the day. Two 
calibrators at the LOQ and ULOQ determined during method validation were used for the 
generation of the calibration curve. The ability of the assay to determine reliable 
concentrations of the analytes was assessed by using Quality Control (QC) samples. Two 
quality control (QC) samples were prepared at a one concentration level (100ng/mL, of each 
analyte and internal standard). The QC samples were used as a reference to determine 
suitability of the calibration curve to calculate concentration levels in unknown samples. The 
obtained calibration curve was used to back-calculate the concentrations of samples. 
Trueness, expressed as bias, was determined at each concentration level.  
 
5 RESULTS AND DISCUSSION 
5.1 Method development 
5.1.1 Chromatography and mass spectrometry 
 
5.1.1.1 Selecting MS parameters 
Each compound was infused separately by a Hamilton syringe (250µl) to the MS for detection 
of the precursor and fragment ions. The daughter ion with highest intensity that was specific 
for its representive biomarker. See table 3  
Collision energies (AU) were selected for the individual analytes through manual tuning. The 
optimal collision energy that optimized the fragmentation of the precursor ion towards the 
fragment ion response was chosen in order to obtain the highest abundance response of the 
fragment ion. See Table 3 and 4. Appendix for the respective ms-spectres for the chosen 
transitions for each analyte.  
 
5.1.1.2 Selecting chromatographic parameters 
When choosing HPLC column, a Waters X Bridge C18 column, (150 x 2.0 mm, with 3 µm 
particles) was compared to a Luna® HILIC Phenomenex (150 x 2.0 mm, 3 µm particles) 
column. On the Waters X Bridge column, which is a traditional reversed- phase 
chromatography column, the retention decreases with increasingly polarity of the analyte. In 
this project, tobacco alkaloids should be separated. The tobacco alkaloids are basic 
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compounds, and are on ionic form when the pH is below their pKa value. On ionic form, such 
analytes show little retention on traditional C-18 sorbents.  
A buffer is frequently used to control the pH, and indirectly the degree of ionization of such 
polar compounds. Phosphate buffers are widely applied in this purpose, since they cover a 
wide pH range and show good buffer capacity. However, in LC-MS/MS application, 
phosphate buffers  must be replaced by volatile alternatives, such as ammonium formate[42]. 
These buffer solutions have inferior buffer capacities than the phosphate buffers, thus they are 
less suited to prevent ionization of the analytes. Because of this problem, the polar alkaloids 
are expected to have poor retention on this column, which was demonstrated during method 
development experiments. On this column, it was difficult to obtain good separation of the 
analytes. Compositions of mobile phase are given in table 4 in the appendix.  
 
The Luna® HILIC Phenomenex columns retain a water-enriched layer on the surface of the 
silica, which facilitates the transfer of polar compounds into the stationary phase for increased 
retention. Separation is achieved through the partitioning of polar solutes from a high 
concentration, water-miscible, organic mobile phase into this hydrophilic environment, 
resulting in increased retention of polar solutes and elution in the order of increasing 
hydrophilicity[47]. On this column, ionization of the alkaloids is an advantage, providing 
optimal condition for separating the selected biomarkers by hydrophilic interactions with the 
sorbent of the column. This column allows retention for polar compounds such as the 
alkaloids, and the elution order is typically the opposite of that for reversed phase with the 
most polar compounds eluting after the non-polar compounds, resulting in an alternative 
selectivity[2, 47]. As expected, better separation was observed on this column compared to 
the Waters-X-bridge. Satisfactory separation of all the analytes was obtained; therefore this 
column was further used in this project. Ammonium phosphate buffer solution (0,1M pH 3) 
and acetonitrile was chosen as mobile phases. Experiments with different mobile phase 
compositions were performed, demonstrating better separation obtained by graded mobile 
phase composition than with isocratic. The best suited gradients for separating the analytes on 




Figure 17 Chromatogram presenting separation of the selected analaytes obtained on the Luna® HILIC 
Phenomenex column. RT: retention time. 
 
5.1.2 Sample preparation 
5.1.2.1 LLE vs. SPE 
Several sample preparation techniques for nicotine and its metabolites in biological specimens 
have been described in the literature; protein precipitation, centrifugal clarification, solid 
phase extraction and liquid-liquid extraction [41, 48-50]. 
Solid phase extraction methods gave the best peak-to-noise ratios in initial experiments, and 







5.1.3.1 HLB  
 
The alkaloids to be extracted with the same sample preparation step had pKa values between 
the range of 4.5 (trans-3 `hydroxycotinine) and 9.5(nornicotine).  
The Oasis HLB sorbent is a copolymer designed with both hydrophilic and lipophilc groups. 
This allows retention of respectively both hydrophilic and lipophilic substances. All the 6 
biomarkers selected in this project are basic compounds. Subjected to an acidic environment, 
the alkaloids are on their ionised form. This allows a stronger interaction to the hydrophilic 
parts of the HLB sorbent.(Figure 18) In the selected sample preparation method, phosphate 
buffer (0.2 M, pH 7) was used to stabilise the urine samples. Trans-3 `hydroxycotinine and 
cotinine have pKa values below this pH. However, the abundance of these metabolites is 
relatively high compared to the minor tobacco alkaloids like anabasine, anatabine and 










Figure 18 Illustration of the sorbent used in the Oasis HLB cartridges[51]  
 
5.1.3.2 Selecting buffer solution 
During the method development of the HLB extraction, a triiodophosphate(pH 13) buffer 
solution was compared with a phosphate(0.2 M , pH 7) buffer solution. The exact same SPE 
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procedure and sample analysis was performed for the two different buffer solutions (See 
figure 18).  
After diluting the urine sample with the tiiodophosphate buffer, the pH of the sample was 
about 12. At this pH, all six compounds are almost entirely on their unionised form. Under 
such conditions, the alkaloids are expected to be better retained by the lipophilc groups of the 
sorbent. Theoretically this would further enhance the recovery of the six biomarkers. 
However, experimentally, using the triiodophosphate buffer, demonstrated only a marginal 
improvement of peak intensity compared to the phosphate buffer.  
The phosphate buffer was selected for this SPE procedure for two reasons; 1) the phosphate 
buffer solution had lower cost than the triiodophosphate buffer, and 2) the triiodophosphate 
buffer had a greater tendency to clog the SPE cartridges during the extraction than the 
phosphate buffer, causing greater concerns regarding the reproducibility of the procedure.  
 
5.1.3.3 HLB vs MCX 
The Oasis MCX (Mixed mode Cation eXchange) polymeric sorbent are designed for solid-
phase extraction of basic compounds from biological matrices (Figure 19). The anionic group 
on the sorbent allows strong ionic interactions with the alkaloids when they are on their 
protonated from. Theoretically, this sorbent would provide better recovery compared to HLB 
where the retention of the analytes is only based on the weaker lipophilic/ hydrophilic 
interactions (Figure 18), thus following MCX extraction method was investigated: 
 
The principal behind this method consisted in acidifying the urine with a HCl solution to 
ionize the alkaloids, and prevent them from binding with proteins. In the next step, the 
cartridges were washed with HCl to assure that the ionized alkaloids got attatched on the ion 
exchanger and proteins removed. Then a second washing step was performed in order to 
remove neutral and acidic interferences trapped by the reversed-phase mechanism of MCX. In 
order to neutralize and elute the alkaloids, a methanolic base was used. The elute was 
collected and further treated as described in the method used on the HLB cartridges. See 













Figure 19 Illustration of the sorbent on Oasis MCX cartridges[51] 
 
The first time the MCX method was tried out, it demonstrated great improvements compared 
to the HLB method results. Same procedure was conducted several times, but these results 
were not reproducible in consecutive experiments, which demonstrated a peak-to-noise ratio 
considerably lower than what was obtained on the previously developed HLB extraction 
method. Why the results from the first attempts were not reproducible is still uncertain. The 
most likely hypotheses are that the centrifugation-step prior to the extraction was forgotten, or 
that some of the solution used in the extraction procedure got mixed up.  
Developing and improving a new solid phase extraction method, is very difficult, time 
consuming and expensive. Due to these issues the MCX method was not further improved. 
When tried out on real samples from smokers, the pre-existing HLB method provided 
sufficient up concentration allowing detection of all analytes. Therefore, the project continued 
with this method. The final HLB method was established after experimentally deciding which 
solution was best suited for the different steps of the extraction. Because of the differences in 
chemical properties of the six detected biomarkers, this decision was based on compromises. 
While deciding the amount of acetonitrile:formiate buffer solution best suited to redissolve 
the evaporated elutent from the SPE, re-dissolving in respectively 100, 250, 500, and 1000µL 
was tested. For the minor tobacco alkaloids, a low amount gave higher peak intensity, 
whereas a high amount was more fitted to nicotine. As a compromise, 500 µL was chosen. 
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5.2 Method Validation 
5.2.1 Selectivity 
The selectivity of the four the internal standars was visually determined by absence of 
interfering peaks at the selected MRM transitions in the negative urine samples. In the 
samples spiked with the IS, one peak appeared in each chromatogram absent in the samples of 
blank urine. This experiment suggests sufficient selectivity of all internal standards in urine 
(Figure 20) Selectivity of nicotine, cotinine, trans-3’-hydroxycotinine, anatabine, anabasine 
and nornicotine was confirmed by the absence of interfering peaks at the selected MRM 
transitions with good peak shape and a S/N of >3 with a RT within ±2% of the corresponding 
deuterated analogue.(Figure 21) Whereas for anatabine and nornicotine, selectivity was 
established by comparing blank urine to urine spiked with the respective standards, since the 
deuterated analogues were not available. Peaks appeared in the urine spiked with the 
standards, and absence of interfering peaks at the selected MRM transitions with a RT within 
±2% of the corresponding analogue demonstrated selectivity of these compounds (Figure 22). 
This experiment ensures the selectivity of the method. 
  
 
Figure 20 Selectivity test of internal standards, no interferences observed in the blank urine at selected MRM 





Figure 21 Selectivity test nornicotine and anabasine, blank (negative) urine compared to spiked urine, no 
interferences observed in the blank urine at selected MRM transitions at ±2% of the RT observed in samples 




Figure 22 Selectivity test nicotine, cotinine, trans-OH cotinine and anatabine. Negative urine was compared 
to the negative urine spiked with IS-only, no interferences observed in the negative urine at selected MRM 




5.2.2 Quantitative validation 
The calibration curve was plotted with nominal concentration to peak area ratios (peak area of 
standard/peak area of internal standard). The peaks were automatically integrated on the 
Xcalibur program, and calibration graphs were generated using Microsoft
®
 Office Excel 2007. 






standard curve fittings were evaluated, and 
un-weighted linear regression was established as the best suited for the detected analytes. 
With un-weighted linear regression, linearity determination coefficients (R
2
) were obtained of 
> 0.985 for nicotine, >0.985 for cotinine, >0.982 for trans-3-hydroxycotinie, >0.980 for 
anatabine and >0.976 for anabasine, and > 0.961 for nornicotine, respectively. Repeatability 
values were estimated to be within ranges of 7.1-13.6 % at each concentration level for all the 
analytes, and intermediate imprecision was estimated at 9.0-15.0%, respectively. Accuracy 
profile for each analyte is given in the Appendix. At all concentration ranges for each analyte, 
the accuracy was estimated to be within acceptance criteria of ± 30 %. In this simplified 
validation method, calibration standards were prepared at only two concentration levels (k=2). 
Additionally, the mean recalculated value should be within 15% of the theoretical value at all 
concentration ranges except for the LLOQ (within 20%). The selected acceptance criteria of ± 
30% is outside these recommendations. For the aim of this project a wider accuracy 
acceptance range was tolerated.  
 
 
Figure 23 Correlation between recalculated values and theoretical values of nicotine. The red points 
represent the mean measured values; the blue lines represent the estimated deviation from the mean. The 
theoretical values should be as close as possible to the measured values. Correlation curves of cotinine, 





Figure 24 Accuracy profile of nicotine, See appendix for accuracy profile of the other analytes. 
 
According to the FDA and ICH guidelines, the standard curve should consist of a minimum of 
six standards points over the entire range of expected concentrations. In order to meet this 
criteria with the selected validation design, the calibration standards should have been 
prepared at three concentration levels (k=3), instead of two.  
In the first attempt of validation, the calibration was performed with three successive series, at 
six calibration standards levels (k=6) and five validation standards concentration levels (k=5), 
prepared in triplicate (n=3). However, sufficient linearity was not obtained.  In the first 
attempts, this was due to wrong composition of solvent used in re-dissolution of the extracted 
samples. The second attempt was unsuccessful presumably due to inaccurate measurements. 
This suspicion was confirmed by six consecutive reinjection of same sample that revealed 
>20% variation in the peak area of standard/peak area of internal standard ratios. The 
equipment got fine tuned, and quantitative validation was reattempted. Satisfying accuracy 
profiles were obtained for all three series. Unfortunately, the working solutions had been 
incorrectly prepared. This was discovered first after fully validation had been completely 
conducted and all data processed. These problems encountered during quantitative validation 
required introduction of a simplified validation. If the method should be applied to routine 
analysis, a more robust quantitative validation must be preformed, including determinations of 
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5.2.3 Method sensitivity 
Method sensitivity was experimentally determined during the quantitative validation. The 
LOQ was defined as the lowest standard in the calibration graph that produced a S/N ratio of 
≥10 for the selected MRM transitions with acceptable precision and accuracy. The LOQ was 
determined as 10ng/mL for nicotine, cotinine and trans-3-hydroxycotinie, anatabine, 
anabasine and nornicotine. Whereas the ULOQ was experimentally demonstrated at 10000 





5.3 Application of the method 
At least one of the QC samples at each concentration levels (>3) should be within 15% of the 
nominal value. In this experiment, only one concentration level of QC samples was prepared, 
of which neither of the duplicates passed the acceptance criteria set by FDA guidelines. 
According to FDA requirements, the run should have been rejected if it was applied in routine 
analysis.  
 
This experiment was conducted with objective to evaluate whether or not the developed 
method could work as intended, thus the result could still provide useful information. 
Regardless of these concerns in relation to the reliability of the method, the results were 
interpreted. 
 
In urine of the cigarette smoker, the analytes were detected within the following concentration 
ranges; 10.5-676.6 ng/mL for nicotine, 202.9-339,0 ng/mL for cotinine, 550-1047 ng/mL for 
trans-3-hydroxycotinie, 9.9-19.8 ng/mL for anatabine, 6.6-15.3 ng/mL for anabasine and 13.3-
63.9 ng/mL for nornicotine.  Whereas for the snuser, the analytes were detected within the 
ranges of 6.1-63.7 ng/mL for nicotine, 133.4-201.8 ng/mL for cotinine, 345.4-416.4 ng/mL 
for trans-3-hydroxycotinie, 345.4-450.1 ng/mL for anatabine, 5.4-7.0 ng/mL for anabasine 






Table 6 Measured analyte concentration (ng/mL), (* = < LOQ, - = < LOD) 
    measured analyte concentration (ng/ml) 
   nicotine cotinine trans-OH-cot anatabine anabasine nornicotine 
cigarette 
samples 
1. sample 676.6 339 1047.5 19.8 15.3 63.9 
2. sample 109.5 202.9 550 9.9* 6.6* 25.8 
3. sample 14.7 269.5 725 - - 13.3 
4. sample 10.5 299.4 937.7 - - 18.3 
snus 
samples 
1. sample 39.4 201.8 416.4 - - 7.5* 
2. sample 63.7 180.9 345.4 5.4* 6.4* 19.6 
3. sample 6.8* 163.1 356.7 7* 6.3* 31.9 
4. sample 6.1* 133.4 450.1 - - 12.7 
 
 
These measurements suggest that smokers accumulate higher levels of nicotine, cotinine and 
trans-3-hydroxycotinie than snusers. The measured urinary concentration of tobacco alkaloids 
is influenced by variations in tobacco product composition, as well as inter-individual 
differences in the pharmacokinetic of the respective alkaloids measured. When urine is 
collected from smokers and snusers after free tobacco use, they tend to have about the same 
nicotine and cotinine levels despite these differences in tobacco composition.This may be 
attributed to individual adjustments of tobacco consumption frequency in order to obtain most 
favourable nicotine plasma concentrations. The participants of this experiment consumed only 
one tobacco-unit each, thus they were not able to compensate for any such influencing factors 
as they presumably would have done in “real” life. Due to these issues, comparing ratio of the 
measured analytes would provide more useful information. 
  
According to the literature, best chances of finding ratio differences are by comparing 
nicotine:cotinine, nicotine:anatabine, and nicotine:anabasine ratios[38]. When interpreting the 
measured results, no such difference was observed in the nicotine:cotinine ratio between the 
snus and cigarette samples(See table 8). However, differences in nicotine:anatabine, 
cotinine:anatabine and trans-3-hydroxycotinie:anabasine  were observed between the two 
groups. The nicotine:anatabine and trans-3-hydroxycotinie:anabasine ratio values were 
remarkable higher in the cigarette samples than in the snus samples, indicating a higher 
consentation of the minor tobacco alkaloids compared to the major tobacco alkaloids in the 
urine of snus users. The same trend was seen in the nicotine:anatabine ratios as well, even 
though there was a slightly overlap between the groups. These findings correlates well with 
 52 
results presented in a published study, where higher nicotine:anatabine ratio in urine of 
smokers than smokeless tobacco users was observed [38].  
 
Table 7 Ratio range intervals. √: overlap of concentration ranges between the two compared groups, ×: 
no overlap in ratio ranges between the groups (This table is a simplified presentation of information from 
table 10, see appendix.) 
investegated ratios 
ratio ranges 
cigarette samples snus samples       overlap 
nicotine: cotinie 0.0-2.0 0.0-0.4 √ 
nicotine: trans-OH-cot 0.0-0.7 0.0-0.2 √ 
nicotine: anatabine 11.1-34.2 1,0-11.8 (√) 
nicotine: anabasine 16.6-44.2 1.1-10.0 × 
nicotine: nornicotine 0.6-10.6 0.2-5.3 √ 
cotinine: anatabine 17.1-20.5 23.3-33.5 × 
cotinine: anabasine 22.2-30.7 25.9-28.3 √ 
cotinine:  nornicotine 5.3-20.3 5.1-29.9 √ 
trans-OH-cot: anatabine 52.3-55.6 51.0-64.0 √ 
trans-OH-cot: anabasine 68.5-83.3 54.0-56.6 × 
trans-OH-cot: nornicotine 16.4-54.5 11.2-55.5 √ 
 
However, these are only preliminary results, and no conclusions can be drawn due to 
inadequate reliability of the method and limited number of samples measured. Still, these 
findings suggest that some of the selected biomarker ratios, especially  
nicotine:anabasine, nicotine:anatabine, cotinine:anatabine, cotinine:anabasine and  





A  LC-MS/MS method for the simultaneous extraction and quantification of nicotine, 
cotinine, trans-3-hydroxycotinie, anatabine, anabasine and nornicotine from human urine has 
been developed and validated. The applied SPE technique, allowed a simple and cost-reduced 
sample preparation. Such considerations are important to make when developing a novel 
methods intended for use in routine screening of prohibited substances.  
Some preliminary results were obtained, especially in concentration ranges of the major 
alkaloids; nicotine, cotinine and trans-3-hydroxycotinie in relationship to the minor tobacco 
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alkaloids; anatabine and anabasine, indicating a higher concentration of minor tobacco 
alkaloids compared to major tobacco alkaloids in the urine of snusers than smokers. These 
findings correlate well with results presented in a published study [38]. These elevated 
amounts are presumably caused by heat induced decomposition of minor tobacco alkaloids 
when the tobacco is burned, such as the case for the smoked tobacco products. This would 
correspondingly lead to lower absorbtion of respective alkaloids by cigarette smokers than by 
smokeless tobacco users, as indicated by these preliminary results. 
Despite promising potential, the developed method was demonstrated as unreliable during the 
method validation for its application in routine work. However, analysis were performed on a 
Luna® HILIC Phenomenex column, thus this project provides interesting information 
concerning its capacity to separate ionic compounds. This column is relatively new on the 
market; hence there is a lack of published studies in which it has been used.  
 
7 FURTHER PERSPECTIVES 
 
If a better sample extraction procedure was obtained, the presented method could have great 
potential to differentiate between the nicotine consumption patterns. The main issues 
concerning this method are inadequate sensitivity and high degree of bias, both parameters 
most plausible linked to the sample preparation step. If there was more time available, the 
MCX sample preparation method described in the method development discussion, would be 
reattempted and improved. If not satisfying result were obtained, there could still be ways to 
achieve better and more accurate sample preparation on the HLB columns. Finding a more 
appropriate buffer solution not clogging the HLB cartridges could be a good strategy to 
improve this method. If it was possible to develop a well functioning SPE method, it should 
further be validated according to FDA and IHC guidelines. Finally, the method must be 
applied in a clinical study of optimal size and  designed in order establish whether or not these 
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9 APPENDIX  
 
9.1 Method validation 








































79.98 146.04 134.04 163.15 57.99 69.94 122.06 107.93 96.22 
std_nic_1ug 
  # 766 RT: 3.69 AV: 1 NL: 6.02E3 F: ITMS + c ESI Full ms2 163.1 [ 50.00-200.00] 
                  












  # 742 RT: 3.59 AV: 1 NL: 5.60E4 F: ITMS + c ESI Full ms2 167.10@25.00 [ 50.00-200.00] 














































86.11 123.05 108.06 
122.03 83.98 97.04 149.10 133.08 111.06 58.12 87.14 72.03 80.95 152.00 165.22 106.18 68.25 
 
Figure 26 Fragmentation pattern of Nicotine-d4 
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Figure 27 Fragmentation pattern of cotinine 
std_nic_1ug 
  # 462 RT: 2.42 AV: 1 NL: 2.45E3 F: ITMS + c ESI Full ms2 177.10@28.00 [ 50.00-200.00] 














































134.01 68.28 94.15 121.21 70.80 110.13 80.98 105.91 150.09 
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Figure 28 Fragmentation pattern of cotinine d-3 
c1010_02 
  # 437 RT: 2.32 AV: 1 NL: 8.41E3 F: ITMS + c ESI Full ms2 180.10@28.00 [ 50.00-200.00] 

















































134.04 138.14 124.07 161.21 73.03 96.19 105.14 113.10 69.98 58.86 180.18 93.81 164.15 
 61 
 
Figure 29 Fragmentation pattern of tans-oh-cotinine 
std_nic_1ug 
  # 506 RT: 2.61 AV: 1 NL: 1.99E3 F: ITMS + c ESI Full ms2 193.10@26.00 [ 50.00-200.00] 










































157.11 165.17 105.95 
144.06 175.08 
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Figure 30 Fragmentation pattern of trans-oh-cotinine-d3 
c1010_02 
  # 510 RT: 2.62 AV: 1 NL: 1.53E4 F: ITMS + c ESI Full ms2 196.10@26.00 [ 50.00-200.00] 
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179.16 153.10 112.12 
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Figure 31 Fragmentation pattern of anatabine 
std_nic_1ug 
  # 1495 RT: 6.73 AV: 1 NL: 3.38E2 F: ITMS + c ESI Full ms2 163.10@25.00 [ 50.00-200.00] 















































136.33 117.99 80.02 
129.15 163.07 92.19 
117.13 105.05 69.82 
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Figure 32 Fragmentation pattern of anatabine-d4 
c1010_02 
  # 751 RT: 3.63 AV: 1 NL: 5.60E4 F: ITMS + c ESI Full ms2 167.10@25.00 [ 50.00-200.00] 




















































Figure 33 Fragmentation pattern of anabasine 
std_nic_1ug 
  # 1495 RT: 6.73 AV: 1 NL: 3.38E2 F: ITMS + c ESI Full ms2 163.10@25.00 [ 50.00-200.00] 















































136.33 117.99 80.02 
129.15 163.07 92.19 
117.13 105.05 69.82 
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  # 1610 RT: 7.21 AV: 1 NL: 5.42E2 F: ITMS + c ESI Full ms2 149.10@26.00 [ 50.00-200.00] 













































9.1.2 Mobile phase gradients  
 
Table 8 HPLC gradient table used on the Waters X Bridge C18 column (3 µm particles, 200 Å pore 
diameters) Solvent A: 0,1 M Formiate buffer pH 3, Solvent B: Methanol 
No Time (min) % Solvent A % Solvent B 
Pressure 
(µl/min) 
0 0 90 10 400 
1 3 90 10 400 
2 7 30 70 400 
3 10 30 70 10 
4 11 90 10 10 
5 13 90 10 10 
 








500 µl Urine sample +(IS) 
500 µl 120mM HCl(120mM pH<2)  
(Spiking IS/ WS) 
 Centrifugation   
2500 rpm for 5 min 
 
SPE: Conditioning 
500 µl MeOH 




500 µl Urine sample + 
500 µl HCl(120mM pH<2) (+IS/) 
 
Wash 1 
1 ml 0,5 M HCl 
 
Wash 2 




250 µl of 5 % NH4OH in CH3OH  
 
 
Figure 35 MCX extraction procedure This solid phase extraction method was 
performed using a Oasis
®
 MCX extraction plate 30 mg, 96-well. 
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9.2 Method validation 
 
 
9.2.1 Trueness and precision 
 
Table 9 Trueness and precision calculated at each concentration level over the 3 days of validation  
Compound 




Intermediate precision (RSD, %) 
Trueness (%) 
nicotine 
10 8.8/11.8 95.80% 
5000 9.1/12.9 95.60% 
8500 13.0/12.9 97.90% 
cotinine 
10 10.9/12.2 99.10% 
5000 9.9/11.6 94.20% 
8500 10.1/12.0 100.10% 
trans-oh-cot 
10 13.4/15.0 100.80% 
5000 10.6/10.9 93.20% 
8500 8.8/9.4 100.50% 
anatabine 
10 12.1/12.6 103.50% 
250 12.6/12.6 96.60% 
400 7.8/10.4 109.50% 
anabasine 
10 7.1/10.9 96.10% 
250 13.6/14.3 98.10% 
400 10.2/10.0 103.40% 
nornicotine 
10 8.9/11.8 99.50% 
250 11.4/13.5 103.50% 


























Figure 36 Accuracy profile of cotinine 
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Accuracy profile Cotinine





























Figure 38 Accuracy profile of trans-OH-cotinine 
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Recalculated values 10-8500 ng/mL of Trans-OH-cotinine
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Figure 40 Accuracy profile of anatabine 
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Accuracy profile Anatabine
























Recalculated values 10-400 ng/mL Anatabine
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Figure 42 Accuracy profile of anabasine 
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Accuracy profile anabasine

























Recalculated values 10-400 ng/ mL of Anabasine
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Figure 44 Accuracy profile of nornicotine 
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Accuracy profile Nornicotine
























Recalculated values 10-400 ng/mL, Nornicotine
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9.2.3 Chromatograms  
 
 

















































9.3 Method application 
9.3.1 Concentration ratios  
 




measured concentrations (ng/mL) 
cigarette samples snus samples 
1. 2. 3. 4. 1.  2. 3. 4. 
nicotine: cotinie 2 0.54 0.05 0.04 0.2 0.35 0.04 0.05 
nicotine: trans-oh-cot 0.65 0.2 0.02 0.01 0.09 0.18 0.02 0.01 
nicotine: anatabine 34.17 11.06 - - - 11.8 0.97 - 
nicotine: anabasine 44.22 16.59 - - - 9.95 1.08 - 
nicotine: nornicotine 10.59 4.24 1.11 0.57 5.25 3.25 0.21 0.48 
cotinine: anatabine 17.12 20.49 - - - 33.5 23.3 - 
cotinine: anabasine 22.16 30.74 - - -  28.27 25.89 - 
cotinine:  nornicotine 5.31 7.86 20.26 16.36 29.91 9.23 5.11 10.5 
trans-oh-cot: anatabine 52.9 55.56 - - - 63.96 50.96 - 
trans-oh-cot: anabasine 68.46 83.33 - - - 53.97 56.62 - 




9.3.2 Trueness and linearity parameters 




































10 10.9 8.7% 100 117.2 17.2% slope 0.1193 
10 9.1 -8.7% 100 114.1 14.1% intercept  0.0619 
10000 10636.6 6.4%    R2values  0.9919 
10000 9363.4 -6.4%           
cotinine 
10 11.4 14.1% 100 86.0 -14.0% slope 0.0182 
10000 8.6 -14.1% 100 102.0 2.0% intercept  0.0385 
100 11036.0 10.4%    R2values  0.9789 
100 8964.0 -10.4%           
trans-oh-
cotinine 
10 9.3 -7.3% 100 115.4 15.4% slope 0.0074 
10 10.7 7.3% 100 90.8 -9.2% intercept  0.0315 
10000 8598.6 -14.0%    R2values  0.9621 
10000 11401.4 14.0%           
anatabine 
10 11.5 15.4% 100 115.4 15.4% slope 0.0010 
10 8.5 -15.4% 100 90.8 -9.2% intercept  0.0024 
500 488.7 -2.3%    R2values  0.9989 
500 511.3 2.3%           
anabasine 
10 11.9 18.8% 100 130.8 30.8% slope 0.0016 
10 8.1 -18.8% 100 83.0 -17.0% intercept  0.0011 
500 467.5 -6.5%    R2values  0.9912 
500 532.5 6.5%           
nornicotine 
10 10.2 2.3% 100 119.0 19.0% slope 0.0024 
10 9.8 -2.3% 100 73.1 -26.9% intercept  0.0057 
500 504.8 1.0%    R2values  0.9998 
500 495.2 -1.0%           
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9.3.3 Chromatograms  
 
 
Figure 48 Chromatogram of urine sample of smoker, 1 h after consummation of 1 cigarette 
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Figure 49 Chromatogram of urine sample from snuser, 1 h after consummation of one snus 
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